mProX™ Human GLP2R Stable Cell Line

Product Information

Target Protein

GLP2R

Target Family

Glucagon Family

Target Protein Species

Human

Host Cell Type

PC9;HCC827;CHO-K1;HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Digestive and Renal Research

Related Diseases

Bowel Dysfunction;Short Bowel Syndrome

Gene ID

Human: 9340

UniProt ID

Human: O95838

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The glucagon-like peptide 2 receptor (GLP2R) has been the subject of various scientific studies, revealing its potential implications in diverse medical conditions. For instance, the GLP-2-GLP2R signaling pathway has been identified as a potential modulator of sensitivity to EGFR-TKIs, a class of drugs used in lung cancer treatment. Additionally, GLP-2R plays a pivotal role in hepatic adaptation to nutrient excess, suggesting its significance in liver-related disorders. Furthermore, GLP2R's involvement in the methylation status among Small for Gestational Age (SGA) patients has been explored, indicating its potential role in growth and development. Collectively, these findings underscore the importance of GLP2R in various physiological processes and its potential as a therapeutic target in multiple diseases.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human GLP2R Stable Cell Line (S01YF-0923-PY79). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Helen (Verified Customer)

What is the role of GLP2-GLP2R signaling in lung cancer treatment? Feb 23 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

The GLP-2-GLP2R signaling may alter the sensitivity of cells to EGFR-TKIs and cisplatin, suggesting its potential benefit in the clinical treatment of lung cancer. Feb 23 2023

chat Timothy (Verified Customer)

How does the loss of Glp2r signaling affect hepatic stellate cells? Feb 10 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

The loss of GLP-2R signaling activates hepatic stellate cells and exacerbates diet-induced steatohepatitis in mice, indicating its essential role in hepatic adaptation to nutrient excess. Feb 10 2023

Published Data

Fig.1 GLP2R expression.

The parental cell line saw an elevation in GLP2R expression through the introduction of overexpression plasmids, denoted as PC-GLP2R-OV or HCC287-GLP2R-OV, via transfection techniques.

Ref: Song, Bin, et al. "GLP2-GLP2R signal affects the viability and EGFR-TKIs sensitivity of PC9 and HCC827 cells." BMC Pulmonary Medicine 22.1 (2022): 1-8.

Pubmed: 35027025

DOI: 10.1186/s12890-021-01800-3

Research Highlights

Valiente PA, et al. "Computational Design of Potent and Selective d-Peptide Agonists of the ." Journal of medicinal chemistry, 2023.
In this study, three d-GLP-2 agonists were developed to specifically activate the glucagon-like peptide-2 receptor (GLP-2R) and increase cyclic adenosine monophosphate (cAMP) accumulation, without stimulating the glucagon-like peptide-1 receptor (GLP-1R). In vitro experiments showed that all three d-GLP-2 agonists increased the expression of phosphorylated protein kinase B (p-AKT) in a time- and concentration-dependent manner. The most effective d-GLP-2 analogue showed a 2.28-fold increase in p-AKT levels compared to the natural l-GLP-2. This enhancement in p-AKT levels could be attributed to the d-GLP-2 agonists' longer activation of GLP-2R and lower recruitment of beta-arrestin. Additionally, these d-GLP-2 agonists have higher stability against protease degradation, indicating potential applications in improving intestinal absorption and treating inflammatory bowel disease, potentially at lower dosages compared to current treatments.
Pubmed: 37491005 DOI: 10.1021/acs.jmedchem.3c00464

Gibadullin R, et al. "Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal ." Journal of the American Chemical Society, 2023.
Class B1 G protein-coupled receptors (GPCRs) have a crucial role in detecting extracellular polypeptide agonists and transmitting their messages to the cell's interior. These receptors need to be able to change their shape in response to agonists, and recent research has shown that the mobility of agonists themselves can impact receptor activation. By studying the GLP-2R receptor and comparing it with the GLP-1R receptor, scientists have discovered that variations in the alpha-helical structure of agonists can have different effects on the two receptors. This knowledge could aid in the development of hormone analogues with unique activity profiles, such as a newly discovered GLE analogue that acts as both a potent agonist of the GLP-2R and a potent antagonist of the GLP-1R, demonstrating a novel form of polypharmacology.
Pubmed: 37235770 DOI: 10.1021/jacs.3c01628